Keratoconus Facts & Statistics

Keratoconus was historically estimated to affect roughly 1 in 2,000 people. However, modern corneal tomography screening has revealed the condition is far more common. A 2017 meta-analysis published in Acta Ophthalmologica estimated a prevalence of approximately 1 in 375 people worldwide. The condition is more frequently diagnosed in populations of South Asian, Middle Eastern, and Hispanic descent. Because early-stage keratoconus often goes undetected with standard eye exams, many cases remain undiagnosed until the cornea has already changed shape significantly.

Keratoconus usually begins during puberty or early adulthood, most often between the ages of 10 and 25. The condition tends to progress for 10 to 20 years before the corneal shape stabilizes. Younger patients at diagnosis are more likely to experience faster progression, making early detection and intervention especially important. Pediatric cases diagnosed before age 15 often represent the most aggressive form of the disease.

The exact cause of keratoconus is not fully understood, but research points to a combination of genetic susceptibility and environmental triggers. Chronic eye rubbing is consistently identified as one of the strongest modifiable risk factors. Atopic conditions such as asthma, eczema, and allergic conjunctivitis are associated with higher keratoconus rates—likely because they increase the tendency to rub the eyes. Studies report that 15% to 67% of keratoconus patients have a first-degree relative with the condition, suggesting a significant hereditary component. Sleep position (face-down sleeping) and floppy eyelid syndrome have also been linked to keratoconus development.

Treatment depends on the stage of the disease. In early stages, glasses or soft contact lenses may still provide adequate vision. As the cornea becomes more irregular, rigid gas permeable (RGP) lenses or scleral lenses are used to create a smooth optical surface over the cone. Scleral lenses vault over the entire cornea and rest on the sclera (white of the eye), making them the most effective non-surgical option for moderate to advanced keratoconus. Approximately 90% of keratoconus patients who are fitted with scleral lenses achieve functional vision and avoid the need for corneal transplant surgery. Corneal cross-linking (CXL), an FDA-approved procedure since 2016, can slow or halt progression by strengthening the collagen bonds within the cornea.

Between 10% and 20% of keratoconus patients eventually require corneal transplant surgery (penetrating keratoplasty or deep anterior lamellar keratoplasty). The rate of transplant has decreased over the past two decades due to advances in specialty contact lens design and the availability of corneal cross-linking. Corneal transplant for keratoconus has a high success rate—over 90% graft survival at 10 years—but the procedure requires prolonged recovery (12 to 18 months) and lifelong follow-up to monitor for graft rejection.

Yes. Keratoconus is a progressive condition, meaning the cornea continues to thin and steepen over time without intervention. Progression is typically fastest in the teenage years and twenties, and usually stabilizes naturally by the mid-30s to 40s. However, the degree and rate of progression vary significantly between individuals. Serial corneal topography (mapping) every 6 to 12 months is the standard method for monitoring progression. Corneal cross-linking can be performed when progression is documented to prevent further corneal weakening.